The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 02, 2021

Filed:

Jan. 03, 2018
Applicants:

Loxo Oncology, Inc., Stamford, CT (US);

Array Biopharma, Inc., Boulder, CO (US);

Inventors:

Nisha Nanda, Stamford, CT (US);

Joshua H. Bilenker, Stamford, CT (US);

James F. Blake, Boulder, CO (US);

Gabrielle R. Kolakowski, Boulder, CO (US);

Barbara J. Brandhuber, Boulder, CO (US);

Steven W. Andrews, Boulder, CO (US);

Assignees:

Loxo Oncology, Inc., Stamford, CT (US);

Array BioPharma, Inc., Boulder, CO (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/519 (2006.01); C12Q 1/6886 (2018.01); A61K 31/5025 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 31/5025 (2013.01); A61K 31/519 (2013.01); G01N 33/57492 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01);
Abstract

Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.


Find Patent Forward Citations

Loading…